South Korea Decentralized Clinical Trial Market Insight
Published: 15 July 2026 | Report Format: Electronic (PDF) | Author: Komal and Radhika
With a projected CAGR of 12.66% from 2025-2035, the decentralized clinical trial market in South Korea is expected to grow significantly due to adoption of digital health and regulatory modernization.
South Korea Decentralized Clinical Trial Market Insights Forecasts to 2035
- The South Korea Decentralized Clinical Trial Market Size Was Estimated USD 139.7 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.66% from 2025 to 2035
- The South Korea Decentralized Clinical Trial Market Size is Expected to rise around USD 460.2 Million by 2035
Notable Insights for the South Korea Decentralized Clinical Trial Market
- According to study design segmentation, the DCT market is dominated by interventional trials, but as real-world evidence becomes more significant, observational and expanded access studies expand. Cloud-based deployment deployment dominating cloud-based deployment deployment deployment.
- DCT adoption is dominated by oncology based on therapeutic application segmentation, with cardiology and CNS disorders growing as a result of the necessity for remote monitoring for chronic illnesses.
- Korea's DCT model development is being led by government-backed projects, such as a five-year investment of 4.5 billion won ($3.3 million) including seven major hospitals.
- With a DCT adoption rate of less than 6% of all clinical trials, South Korea is well behind the $4.6 billion US market and the $2.3 billion European market.
Download the eBook (ToC)
Why Buy This Report
- This report will help you understand the South Korea decentralized clinical trial market. It will tell you what is making it grow and what the rules are.
- It enables data-driven R&D and growth decisions by identifying important investment possibilities across therapeutic categories like as oncology and chronic diseases.
- The report will also tell you about the companies that are doing well in the South Korea decentralized clinical trial market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea decentralized clinical trial market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Decentralized Clinical Trial Market
- Medidata Solutions (Dassault Systèmes)
- IQVIA
- JNPMEDI
- Labcorp (Covance)
- PPD (Thermo Fisher Scientific)
- Parexel
- Seoul National University Hospital (Clinical Trial Center)
- KoNECT (Korea National Enterprise for Clinical Trials)
- Trial Informatics
- ICON plc
Recent Developments:
- In August 2025, Parexel hired a person to oversee sales. This person is going to help Parexel grow its business and make its clinical development better.
- In March 2025, a company made its patient-centric decentralized clinical trial technology available in than 75 countries. This technology uses intelligence and is going to help the South Korea Decentralized Clinical Trial Market grow.
Market Segmentation:
South Korea Decentralized Clinical Trial Market, By Study Design
- Interventional Trials
- Observational Trials
- Expanded Access
South Korea Decentralized Clinical Trial Market, By Therapeutic Application
- Oncology
- Cardiology
- CNS Disorders
South Korea Decentralized Clinical Trial Market, By Deployment Mode
- Cloud-based DCT Platforms
- On-premises Solutions
Expert Views:
There will be tremendous growth in South Korea's clinical trial market because of the growing use of digital health, changes in regulations, and government initiatives. In addition to the growth of interventional trials in oncology, there is an increasing focus on the use of observation trials and chronic diseases. The global market penetration is low, but due to the above factors, the market will grow until 2035.
Author: Komal and Radhika By Decisions Advisors and Consulting